KRAS and cancer: Given the high need to treat cancers driven by CTNNB1, KRAS and MYC oncogenes, we extended the Anova analyses of Fig 6 to all compounds tested, and ranked them on the basis of their relative sensitivities for cell lines expressing these cancer genes (Fig 7).